Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $45.97 and traded as high as $49.61. Global X Genomics & Biotechnology ETF shares last traded at $49.51, with a volume of 13,468 shares changing hands.

Global X Genomics & Biotechnology ETF Stock Performance

The stock has a fifty day moving average of $45.21 and a 200-day moving average of $45.97. The company has a market cap of $55.45 million, a PE ratio of -21.16 and a beta of 1.19.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds have recently made changes to their positions in GNOM. Jane Street Group LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after buying an additional 10,308 shares during the period. Sei Investments Co. lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after buying an additional 12,105 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after buying an additional 4,615 shares during the period. IFP Advisors Inc lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 20.8% in the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after buying an additional 489 shares during the period. Finally, U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth $575,000. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.